VRT.CN - Veritas Pharma Inc.

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
-0.0100 (-7.14%)
At close: 2:15PM EST
Stock chart is not supported by your current browser
Previous Close0.1400
Bid0.1150 x 0
Ask0.1400 x 0
Day's Range0.1300 - 0.1400
52 Week Range0.0850 - 1.2500
Avg. Volume6,702
Market Cap1.58M
Beta (5Y Monthly)0.55
PE Ratio (TTM)N/A
EPS (TTM)-0.9590
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Veritas Announces the Sale of the Sechelt Property

    Veritas Announces the Sale of the Sechelt Property

    Vancouver, British Columbia--(Newsfile Corp. - December 9, 2019) - Veritas Pharma Inc.'s (CSE: VRT) (OTC: VRTHF) (Frankfurt: 2VP) ("Veritas" or the "Company") is pleased to announce that its fully owned subsidiary the Sechelt Organic Marijuana Corp. has completed the sale of its property located in Sechelt, BC, to Lis Holdings Ltd. for cash consideration of $350,000.This property was originally purchased in February 2015 with plans to construct a medical cannabis production facility under the ...

  • GlobeNewswire

    Veritas Reaches a Mutual Settlement with Arbutus Biopharma Corporation

    As a part of the mutual settlement, no party has admitted any liability and there has not been any court finding as to the merits of the lawsuit.  However, to avoid the expense, burden, and uncertainty of the lawsuit, Veritas has entered into a confidential settlement that will resolve the litigation completely.

  • GlobeNewswire

    Veritas Announces the Sale of 3 Carbon Extractions Inc.

    VANCOUVER, British Columbia, July 10, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has completed the.

  • GlobeNewswire

    Veritas Announces Restructuring of Cannevert Therapeutics Ltd.

    VANCOUVER, British Columbia, May 15, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has undertaken steps.

  • GlobeNewswire

    Veritas Announces the Completion of Clinical Trial on their Cannabis Product for Treatment of Acute Pain

    SAN JUAN, Puerto Rico, May 15, 2019 -- Veritas Pharma Puerto Rico, Inc., a wholly owned subsidiary of Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP).

  • GlobeNewswire

    Veritas Pharma Provides Corporate Update

    2018 and the first quarter of 2019 has been a transition period for Veritas Pharma, as the company has matured from being purely engaged in research and development to establishing a viable option for cannabis production in Canada, setting the stage for potential commercialization given positive clinical trial results on its lead pain treatment and appointing new leadership to the company.

  • GlobeNewswire

    Veritas Pharma to Commence Legal Proceedings Against Liht Cannabis

    VANCOUVER, British Columbia, March 04, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it has filed a claim.

  • GlobeNewswire

    Veritas Enrolls First Patient in Clinical Study to Assess Pain Control with Lead Product

    CTL-X, supplied by one of Puerto Rico’s notable cannabis performers, the Institute for Medical Cannabis (“IMC”), will be evaluated on its analgesic properties on simulated pain using standardized pain scales. The clinical research organization, Fundación de Investigación (“FDI”), administered the trial drug in the phase II-III unit at their state-of-the-art facility.

  • GlobeNewswire

    Veritas Pharma Enters into agreement to acquire Commercial Hemp and Cannabis Processing Facility

    Veritas’ director, Nick Standish, commented, “this is an exciting development for Veritas as it further develops our ability to commercialize our proprietary hemp and cannabis products, in addition to expanding our production potential to topical creams and edibles along with oil extracts.

  • GlobeNewswire

    Veritas Pharma Announces the Resignation of CEO, Dr. Lui Franciosi

    Dr. Franciosi stated, “It has been a challenging year with the regulatory delays in starting the Puerto Rico human study of CTL-X and the need to raise funds for medical cannabis research.  I am pleased to see the study approval has finally come through and that potential funding for Cannevert’s important scientific work has been secured, which means that the Veritas and Cannevert are now set for growth under new leadership. Mr. McFadden stated, “The Veritas Board would like to thank Lui for his commitment to investors and to advancing the science behind medical cannabis.”  Dr. Franciosi will continue to assist both companies in an operational capacity.

  • GlobeNewswire

    Veritas leads Puerto Rico partnership with approval of new Investigation License

    IMC and FDI represent two of Puerto Rico’s leading researchers in medicinal cannabis. The concession is also the first of its kind, representing the first collaboration of such by local partners and a foreign-owned and publicly-traded entity.

  • GlobeNewswire

    Veritas Pharma to Proceed with Share Consolidation

    VANCOUVER, British Columbia, Feb. 04, 2019 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) announces that it is proceeding with a.